Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.72 |
| ▸ | EGFR | P00533 | 13/20 | 0.72 |
| ▸ | FLT1 | P17948 | 13/20 | 0.72 |
| ▸ | FGFR1 | P11362 | 12/20 | 0.72 |
| ▸ | FLT4 | P35916 | 11/20 | 0.72 |
| ▸ | RET | P07949 | 2/20 | 0.70 |
| ▸ | KIF5B | P33176 | 2/20 | 0.70 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.62 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.61 |
| ▸ | TEK | Q02763 | 2/20 | 0.61 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.61 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.61 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.61 |
| ▸ | PLK4 | O00444 | 1/20 | 0.61 |
| ▸ | CIT | O14578 | 1/20 | 0.61 |
| ▸ | GAK | O14976 | 1/20 | 0.61 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.61 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.61 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.61 |
| ▸ | STK10 | O94804 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL27735443 | 0.99 | KDR (0.71) | KDREGFRFLT1FGFR1FLT4 | |
| Hydrochloric Acid SCHEMBL6454560 | 0.99 | KDR (0.71) | KDREGFRFLT1FGFR1FLT4 | |
| Trifluoroacetic Acid SCHEMBL6902285 | 0.93 | KDR (0.65) | KDREGFRFLT1FGFR1FLT4 | |
| SCHEMBL2200924 | 0.91 | KDR (0.74) | KDREGFRFLT1FGFR1FLT4 | |
| SCHEMBL2203010 | 0.90 | FLT1 (0.73) | KDREGFRFLT1FGFR1FLT4 | |
| Hydrochloric Acid SCHEMBL7477739 | 0.90 | FLT1 (0.75) | KDREGFRFLT1FGFR1FLT4 | |
| SCHEMBL2200083 | 0.89 | EGFR (0.73) | KDREGFRFLT1FGFR1FLT4 | |
| SCHEMBL5506368 | 0.86 | EGFR (0.56) | KDREGFRFLT1FGFR1FLT4 | |
| SCHEMBL4604150 | 0.85 | KDR (0.64) | KDREGFRFLT1FGFR1FLT4 | |
| SCHEMBL1612820 | 0.85 | KDR (0.84) | KDREGFRFLT1FGFR1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4110796-A1 | CHIMERIC FUSIONS BETWEEN C4-BINDING PROTEIN C-TERMINAL SEGMENT AND ANGIOPOIETIN-1 FIBRINOGEN-LIKE DOMAIN AS ANGIOPOIETIN MIMETICS AND TIE2 AGONISTS TO TREAT VASCULAR DISEASES | Northwestern University (US) | 2023-01-04 | — | — | EP | claimed |
| EP-1620104-A1 | THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE | Astrazeneca AB (SE) | 2006-02-01 | — | — | EP | claimed |
| EP-1592423-A2 | COMBINATION THERAPY OF ZD6474 WITH 5-FU AND/OR CPT-11 | Astrazeneca AB (SE) | 2005-11-09 | — | — | EP | claimed |
| WO-2004098604-A1 | THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | WO | claimed |
| WO-2004071397-A2 | COMBINATION THERAPY OF ZD6474 WITH 5-FU OR/AND CPT-11 | ASTRAZENECA AB (SE) | 2004-08-26 | — | — | WO | claimed |
| JP-3522727-B2 | — | — | 2004-04-26 | — | — | JP | claimed |
| JP-2003513089-A | — | — | 2003-04-08 | — | — | JP | claimed |
| EP-1272186-A1 | THERAPEUTIC COMBINATIONS OF ANTIHYPERTENSIVE AND ANTIANGIOGENIC AGENTS | AstraZeneca AB (SE) | 2003-01-08 | — | — | EP | claimed |
| EP-1244647-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | AstraZeneca AB (SE) | 2002-10-02 | — | — | EP | claimed |
| WO-2001074360-A1 | THERAPEUTIC COMBINATIONS OF ANTIHYPERTENSIVE AND ANTIANGIOGENIC AGENTS | ASTRAZENECA AB (SE) | 2001-10-11 | — | — | WO | claimed |
| WO-2001032651-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ASTRAZENECA AB (SE) | 2001-05-10 | — | — | WO | claimed |
| EP-3835318-B1 | FC-REGION VARIANTS WITH MODIFIED FCRN- AND MAINTAINED PROTEIN A-BINDING PROPERTIES | HOFFMANN LA ROCHE (CH) | 2025-10-29 | — | — | EP | disclosed |
| WO-2023212294-A1 | ANGIOPOIETIN-RELATED PROTEIN 7-SPECIFIC ANTIBODIES AND USES THEREOF | BROADWING BIO LLC (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023212293-A1 | COMPLEMENT FACTOR H RELATED 4-SPECIFIC ANTIBODIES AND USES THEREOF | BROADWING BIO LLC (US) | 2023-11-02 | — | — | WO | disclosed |
| EP-4251206-A1 | PROTEIN DERIVATIVES CONTAINING UNNATURAL AMINO ACIDS AND BRANCHED LINKERS | Brickbio, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| WO-2003039551-A1 | COMBINATION THERAPY COMPRISING ZD6474 AND A TAXANE | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
| EP-1272186-A1 | THERAPEUTIC COMBINATIONS OF ANTIHYPERTENSIVE AND ANTIANGIOGENIC AGENTS | AstraZeneca AB (SE) | 2003-01-08 | — | — | EP | disclosed |
| EP-1244647-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | AstraZeneca AB (SE) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001074360-A1 | THERAPEUTIC COMBINATIONS OF ANTIHYPERTENSIVE AND ANTIANGIOGENIC AGENTS | ASTRAZENECA AB (SE) | 2001-10-11 | — | — | WO | disclosed |
| WO-2001032651-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ASTRAZENECA AB (SE) | 2001-05-10 | — | — | WO | disclosed |